The Manufacturers Life Insurance Company Trims Holdings in Immunome, Inc. $IMNM

The Manufacturers Life Insurance Company lowered its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 12.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 206,799 shares of the company’s stock after selling 30,471 shares during the period. The Manufacturers Life Insurance Company’s holdings in Immunome were worth $4,523,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in IMNM. Quantinno Capital Management LP acquired a new stake in shares of Immunome in the 1st quarter worth $222,000. Aristotle Atlantic Partners LLC acquired a new position in shares of Immunome during the 1st quarter valued at about $2,734,000. Renaissance Technologies LLC acquired a new position in shares of Immunome during the 1st quarter valued at about $1,507,000. Sei Investments Co. grew its holdings in shares of Immunome by 90.4% in the first quarter. Sei Investments Co. now owns 52,770 shares of the company’s stock valued at $1,154,000 after purchasing an additional 25,051 shares during the period. Finally, Walleye Capital LLC purchased a new stake in shares of Immunome in the first quarter valued at about $2,432,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Immunome Trading Up 1.2%

NASDAQ IMNM opened at $25.82 on Friday. The stock has a fifty day simple moving average of $21.43 and a 200-day simple moving average of $22.14. The stock has a market cap of $2.92 billion, a PE ratio of -10.85 and a beta of 2.08. Immunome, Inc. has a twelve month low of $8.66 and a twelve month high of $27.65.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.12. Research analysts predict that Immunome, Inc. will post -2.06 EPS for the current year.

Insider Buying and Selling at Immunome

In other news, insider Kinney Horn sold 90,616 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total value of $2,273,555.44. Following the sale, the insider directly owned 50,366 shares of the company’s stock, valued at approximately $1,263,682.94. The trade was a 64.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jean Jacques Bienaime acquired 10,500 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was bought at an average price of $19.45 per share, for a total transaction of $204,225.00. Following the completion of the acquisition, the director owned 43,415 shares in the company, valued at approximately $844,421.75. The trade was a 31.90% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders sold 562,758 shares of company stock valued at $12,536,203. 7.21% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms recently issued reports on IMNM. Wall Street Zen cut shares of Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Leerink Partners dropped their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a report on Friday, July 17th. Wedbush reaffirmed an “outperform” rating and set a $31.00 price target on shares of Immunome in a research report on Tuesday, July 21st. Finally, Truist Financial upped their price objective on Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, May 28th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.18.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.